Clinical Trial Update: Regorafenib Versus Placebo to Treat Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating regorafenib versus placebo for cholangiocarcinoma is reported, status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Erasme University Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: UNKNOWN